Eli Lilly's once-weekly insulin, efsitora alfa, met non-inferior A1C reduction in type 2 diabetes patients.

Eli Lilly's once-weekly insulin, efsitora alfa, met the primary endpoint in two phase 3 clinical trials, demonstrating non-inferior A1C reduction in type 2 diabetes patients. The results show that efsitora is as effective as daily insulin treatments. The study results come ahead of Novo Nordisk's once-weekly competitor, insulin icodec, being reviewed by the US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee.

May 16, 2024
13 Articles